Kathleen A Lee1, Michelle N Gong2. 1. Department of Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI. 2. Division of Critical Care Medicine, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY. Electronic address: MGong@montefiore.org.
Abstract
BACKGROUND: Pre-B-cell colony-enhancing factor (PBEF) is a potential biomarker for acute lung injury (ALI) in sepsis. We aimed to determine the clinical correlates for elevated plasma PBEF upon ICU admission for severe sepsis and the usefulness of PBEF to predict ALI development and sepsis mortality. METHODS: This is a prospective cohort of patients admitted to the medical ICU with severe sepsis. Patients without available blood samples or who were not enrolled within 24 h of admission were excluded. Plasma collected within 24 h of ICU admission was measured for PBEF concentrations by enzyme-linked immunosorbent assay. Patients were followed for ALI development as defined by the American-European Consensus Conference and for all-cause hospital mortality. RESULTS: Between September 30, 2008, and March 10, 2009, 113 patients were enrolled, and 50 (44%) developed ALI. Elevated PBEF levels significantly correlated with higher APACHE (Acute Physiology and Chronic Health Evaluation) III scores (R(2) = 0.08, P = .003) and failure to reach early sepsis goals within 6 h of severe sepsis (P = .003). PBEF did not differ by ALI status (P = .58). The mortality rate was 46%. Nonsurvivors had higher PBEF levels than survivors (2.53 ng/mL; interquartile range [IQR], 1.07-8.16 vs 1.44 ng/mL; IQR, 0.84-2.81; P = .02). After adjusting for severity of illness, PBEF levels were no longer significantly associated with mortality (OR, 1.44 per 10-fold increase; 95% CI, 0.69-3.03, P = .34). CONCLUSIONS: In this study, elevated PBEF did not correlate with lung injury in sepsis. However, it was associated with sepsis mortality mainly due to its association with greater severity of illness on ICU admission.
BACKGROUND:Pre-B-cell colony-enhancing factor (PBEF) is a potential biomarker for acute lung injury (ALI) in sepsis. We aimed to determine the clinical correlates for elevated plasma PBEF upon ICU admission for severe sepsis and the usefulness of PBEF to predict ALI development and sepsis mortality. METHODS: This is a prospective cohort of patients admitted to the medical ICU with severe sepsis. Patients without available blood samples or who were not enrolled within 24 h of admission were excluded. Plasma collected within 24 h of ICU admission was measured for PBEF concentrations by enzyme-linked immunosorbent assay. Patients were followed for ALI development as defined by the American-European Consensus Conference and for all-cause hospital mortality. RESULTS: Between September 30, 2008, and March 10, 2009, 113 patients were enrolled, and 50 (44%) developed ALI. Elevated PBEF levels significantly correlated with higher APACHE (Acute Physiology and Chronic Health Evaluation) III scores (R(2) = 0.08, P = .003) and failure to reach early sepsis goals within 6 h of severe sepsis (P = .003). PBEF did not differ by ALI status (P = .58). The mortality rate was 46%. Nonsurvivors had higher PBEF levels than survivors (2.53 ng/mL; interquartile range [IQR], 1.07-8.16 vs 1.44 ng/mL; IQR, 0.84-2.81; P = .02). After adjusting for severity of illness, PBEF levels were no longer significantly associated with mortality (OR, 1.44 per 10-fold increase; 95% CI, 0.69-3.03, P = .34). CONCLUSIONS: In this study, elevated PBEF did not correlate with lung injury in sepsis. However, it was associated with sepsis mortality mainly due to its association with greater severity of illness on ICU admission.
Authors: G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg Journal: Am J Respir Crit Care Med Date: 1994-03 Impact factor: 21.405
Authors: Marc Moss; Polly E Parsons; Kenneth P Steinberg; Leonard D Hudson; David M Guidot; Ellen L Burnham; Stephanie Eaton; George A Cotsonis Journal: Crit Care Med Date: 2003-03 Impact factor: 7.598
Authors: Michelle Ng Gong; B Taylor Thompson; Paige Williams; Lucille Pothier; Paul D Boyce; David C Christiani Journal: Crit Care Med Date: 2005-06 Impact factor: 7.598
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: David F Gaieski; Mark E Mikkelsen; Roger A Band; Jesse M Pines; Richard Massone; Frances F Furia; Frances S Shofer; Munish Goyal Journal: Crit Care Med Date: 2010-04 Impact factor: 7.598
Authors: Radu C Oita; Sara M Camp; Wenli Ma; Ermelinda Ceco; Mark Harbeck; Patrick Singleton; Joe Messana; Xiaoguang Sun; Ting Wang; Joe G N Garcia Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: Christian Bime; Sara M Camp; Nancy Casanova; Radu C Oita; Juliet Ndukum; Heather Lynn; Joe G N Garcia Journal: Transl Res Date: 2020-06-26 Impact factor: 7.012
Authors: Alexander Koch; Ralf Weiskirchen; Alexander Krusch; Jan Bruensing; Lukas Buendgens; Ulf Herbers; Eray Yagmur; Ger H Koek; Christian Trautwein; Frank Tacke Journal: Dis Markers Date: 2018-08-26 Impact factor: 3.434
Authors: Hector Quijada; Tadeo Bermudez; Carrie L Kempf; Daniel G Valera; Alexander N Garcia; Sara M Camp; Jin H Song; Evelyn Franco; Jessica K Burt; Belinda Sun; Joseph B Mascarenhas; Kimberlie Burns; Amir Gaber; Radu C Oita; Vivian Reyes Hernon; Christy Barber; Liliana Moreno-Vinasco; Xiaoguang Sun; Anne E Cress; Diego Martin; Zhonglin Liu; Ankit A Desai; Viswanathan Natarajan; Jeffrey R Jacobson; Steven M Dudek; Christian Bime; Saad Sammani; Joe G N Garcia Journal: Eur Respir J Date: 2021-05-06 Impact factor: 33.795